Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori.
about
Novel therapeutic targets in Helicobacter pylori.Clinical application of pharmacogenomics.Enhanced production of leptin in gastric fundic mucosa with Helicobacter pylori infection.Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.Impact of Helicobacter pylori infection on ghrelin and various neuroendocrine hormones in plasma.High concentrations of human beta-defensin 2 in gastric juice of patients with Helicobacter pylori infection.Pharmacogenetics-based new therapeutic concepts.Roles of histamine and its receptors in allergic and inflammatory bowel diseases.Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection.The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.An open-label, randomized, cross-over bioequivalence study of lafutidine 10 mg under fasting conditionImpact of Helicobacter pylori infection on gastric and plasma ghrelin dynamics in humans.
P2860
Q33195402-B52D6837-7962-4868-A87A-838A2DE506AAQ34280685-3A544DF0-8593-4D5E-B6EB-C51BD2C61535Q34605414-F18E32C0-EE76-4043-8063-A77ABFC131D9Q34706721-D4297D74-C4BD-4513-8B5B-7FE963EEDDAAQ35011360-B4F0E483-2F2F-4E73-853C-DF5EFE65A3D4Q35011372-9D28BB55-E2E3-41D3-A000-84B26920D71AQ35435617-FBB592CB-C5D5-4569-87FA-E6665CF1B6EAQ35956177-2A8187A1-D481-471F-9D4A-7086229EA94AQ36132180-B0879557-4C4F-44D1-A1C7-BB7C39919C73Q36177968-50B7CE5C-EA85-4338-A690-E1251CD07A1EQ36545135-B8D8CF17-E2F3-49D4-912D-063D74AFBBD7Q41914881-54ED80BC-9B29-4BAC-9D73-82AFF1B2A9ACQ46639998-16A37CCB-2962-47F3-9A44-7CBC6720C50D
P2860
Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Lafutidine, a novel histamine ...... cation of Helicobacter pylori.
@en
Lafutidine, a novel histamine ...... cation of Helicobacter pylori.
@nl
type
label
Lafutidine, a novel histamine ...... cation of Helicobacter pylori.
@en
Lafutidine, a novel histamine ...... cation of Helicobacter pylori.
@nl
prefLabel
Lafutidine, a novel histamine ...... cation of Helicobacter pylori.
@en
Lafutidine, a novel histamine ...... cation of Helicobacter pylori.
@nl
P2093
P2860
P1433
P1476
Lafutidine, a novel histamine ...... cation of Helicobacter pylori.
@en
P2093
Hajime Isomoto
Hisashi Furusu
Hitoshi Nishiyama
Ikuo Murata
Katsuhisa Omagari
Kenichiro Inoue
Kunihiko Murase
Saburo Shikuwa
Shigeru Kohno
Yohei Mizuta
P2860
P304
P356
10.1046/J.1523-5378.2003.00131.X
P577
2003-04-01T00:00:00Z